

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Kozuki 1



Section 1. Identifying In	formation					
1. Given Name (First Name) Toshiyuki	2. Surnam Kozuki	ne (Last Nan	ne)		3. Date 06-January-2020	
4. Are you the corresponding author?	✓ Yes	No				
<ul><li>5. Manuscript Title</li><li>Open-label, multicenter, randomiz</li><li>treatment of elderly (aged ≥75 yea</li><li>6. Manuscript Identifying Number (if year)</li></ul>	ars) patients with	•	•		•	
Section 2. The Work Und						
The Work Und	er Considerat	ion for P	ublication			
Did you or your institution <b>at any time</b> any aspect of the submitted work (incl statistical analysis, etc.)?  Are there any relevant conflicts of	uding but not limi	ited to gran				c.) for
Section 3. Relevant finan	icial activities	outside '	the submitted	work.		
Place a check in the appropriate be of compensation) with entities as colicking the "Add +" box. You shou Are there any relevant conflicts of If yes, please fill out the appropriate	described in the ld report relation interest?	instructior nships tha es	ns. Use one line fo	or each ent	ity; add as many lines as you need	
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Chugai Pharmaceutical Co.	<b>√</b>	<b>✓</b>				
AstraZeneca	<b>✓</b>	<b>✓</b>				
ili Lilly Japan	<u> </u>	<b>✓</b>				
āiho	<u> </u>	<b>✓</b>				
Bristol-Myers Squibb	<b>✓</b>	<b>✓</b>				
Ono		<b>✓</b>				
<b>NSD</b>		<b>✓</b>				
Pfizer Japan		<b>✓</b>				

Kozuki 2



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Kyowa Hakko Kirin		<b>√</b>				
Nippon Beohringer Ingelheim		<b>✓</b>				
Merck Biophama	<b>✓</b>					
Nippon Kayaku		<b>✓</b>				
Novartis		<b>✓</b>				
Section 4. Intellectual Propert	y Pate	ents & Cop	oyrights			
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo						
Section 5. Relationships not o	overed	above				
Are there other relationships or activities potentially influencing, what you wrote i				nfluenced	d, or that give the appearance of	
Yes, the following relationships/cond	litions/cir	cumstance	s are present (exp	olain belo	w):	
No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.						
Section 6. Disclosure Stateme	nt					
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.						
Dr. Kozuki reports grants and personal for grants and personal fees from Eli Lilly Ja						

Kozuki 3

Myers Squibb, personal fees from Ono, personal fees from MSD, personal fees from Pfizer Japan, personal fees from Kyowa Hakko Kirin, personal fees from Nippon Beohringer Ingelheim, grants from Merck Biophama, personal fees from Nippon

Kayaku, personal fees from Novartis, outside the submitted work; .



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Kozuki 4



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Information	ation			
1. Given Name (First Name) Naoyuki	2. Surname (Last Name) Nogami		3. Date 09-May-2020	
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Toshiyuki Kozuki	s Name	
<ul> <li>5. Manuscript Title</li> <li>Open-label multicenter randomized phaelderly (≥75 years old) patients with presented.</li> <li>6. Manuscript Identifying Number (if you known than 19-734)</li> </ul>	viously untreated advanc	-	•	
Section 2. The Work Under Co	u sido u stio u fou Dubli	4:		
The Work Under Co	nsideration for Public	cation		
Did you or your institution <b>at any time</b> received any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interest	but not limited to grants, da			
Section 3. Relevant financial a	activities outside the s	submitted work.		
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should report there any relevant conflicts of interests.	oed in the instructions. Us ort relationships that wer st?	se one line for each enti	ty; add as many lines as you r	need by
If yes, please fill out the appropriate info	rmation below.			
Name of Entity	Grant? Personal Nor	n-Financial other?	Comments	
MSD K.K				
AstraZeneca K.K				
Kyowa Hakko Kirin Co., Ltd	<b>V</b>			
TAIHO PHARMACEUTICAL CO., LTD.	<b>✓</b>			
Chugai Pharmaceutical Co., Ltd.	<b>✓</b>			
Nikkei Business Publications, Inc.				
Eli Lilly Japan K.K.				
Pfizer Japan INC.				



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Bristol-Myers K.K		<b>✓</b>				
ONO PHARMACEUTICAL CO., LTD.	<b>✓</b>	$\checkmark$				
Nippon Beohringer Ingelheim Co., Ltd.	<b>✓</b>	<b>✓</b>				
Matsuyama Association of Obstetricians and Gynecologists		<b>✓</b>				
Reno. Medical K.K.		<b>✓</b>				
Ehime Medical Association		<b>✓</b>				
Ehime University Graduate School of Medicine		<b>✓</b>				
Auintiles Transnational Japan K.K.		<b>✓</b>				
Section 4.  Intellectual Property Patents & Copyrights  Do you have any patents, whether planned, pending or issued, broadly relevant to the work?   Yes ✓ No						
Section 5. Relationships not c	overed	above				
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.  On occasion, journals may ask authors to disclose further information about reported relationships.						



Section 6.

**Disclosure Statement** 

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Nogami reports personal fees from MSD K.K, personal fees from AstraZeneca K.K, grants and personal fees from Kyowa Hakko Kirin Co., Ltd, grants and personal fees from TAIHO PHARMACEUTICAL CO., LTD., grants and personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Nikkei Business Publications, Inc., personal fees from Eli Lilly Japan K.K., personal fees from Pfizer Japan INC., personal fees from Bristol-Myers K.K, grants and personal fees from ONO PHARMACEUTICAL CO., LTD., grants and personal fees from Nippon Beohringer Ingelheim Co., Ltd., personal fees from Matsuyama Association of Obstetricians and Gynecologists, personal fees from Reno. Medical K.K., personal fees from Ehime Medical Association, personal fees from Ehime University Graduate School of Medicine, personal fees from Auintiles Transnational Japan K.K., outside the submitted work;

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Hataji 1



Section 1.	Identifying Information							
1. Given Name (Fir Osamu	st Name)	2. Surnar Hataji	ne (Last Nar	ne)		3. Date 06-January-2020		
4. Are you the corn	esponding author?	Yes ✓ No Corresponding Author's Name Toshiyuki Kozuki						
treatment of elde	icenter, randomized ph	tients wit	•	•		pemetrexed plus bevacizumab f n-squamous non-small-cell lung	or	
Section 2.	The Work Under Co	nsiderat	tion for P	ublication				
any aspect of the s statistical analysis,	titution <b>at any time</b> receivubmitted work (including	ve paymen but not lim	t or services	from a third party its, data monitoring		ent, commercial, private foundation, udy design, manuscript preparation,		
Section 3.	Relevant financial a	activities	outside	the submitted	work.			
of compensation clicking the "Add Are there any rele	) with entities as descril	oed in the ort relation st?	instruction Inships tha	ns. Use one line fo	or each er	cial relationships (regardless of ar ntity; add as many lines as you ne e 36 months prior to publicatio	ed by	
Name of Entity		Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
Novartis Pharm			<b>√</b>		<b>✓</b>	Research funding		
Boehringer Ingelheim	1		<b>✓</b>		<b>✓</b>	Research funding		
AstraZeneca			<b>✓</b>		<b>✓</b>	Research funding		
Kyorin Pharm					<b>✓</b>	Research funding		
Bayer Health Care					<b>✓</b>	Research funding		
Daiichi Sankyo					<b>✓</b>	Research funding		
Glaxo Smith Kline					<b>✓</b>	Research funding		
Ono Pharm					<b>✓</b>	Research funding		

Hataji 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Hataji reports personal fees and other from Novartis Pharm, personal fees and other from Boehringer Ingelheim, personal fees and other from AstraZeneca, other from Kyorin Pharm, other from Bayer Health Care, other from Daiichi Sankyo, other from Glaxo Smith Kline, other from Ono Pharm, outside the submitted work; .

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Hataji 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not **Royalties:** Funds are coming in to you or your institution due to your

**koyaities:** Funds are coming in to you or your institution due to your patent

Tsunezuka 1



Section 1.	Identifying Inform	nation		
1. Given Name (Fii Yoshio	rst Name)	2. Surname (Last Name) Tsunezuka		3. Date 06-January-2020
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author's Nam Toshiyuki Kozuki	ne
treatment of eld	ticenter, randomized pl	atients with previously un	plus bevacizumab or pemet treated advanced non-squai	trexed plus bevacizumab for mous non-small-cell lung
Section 2.	The Work Under Co	onsideration for Publi	cation	
any aspect of the s statistical analysis,	ubmitted work (including	but not limited to grants, da	a third party (government, con Ita monitoring board, study des	nmercial, private foundation, etc.) for sign, manuscript preparation,
Section 3.	Relevant financial	activities outside the s	submitted work.	
of compensation clicking the "Add	) with entities as descri	bed in the instructions. Use port relationships that we	se one line for each entity; ac	ationships (regardless of amount dd as many lines as you need by <b>onths prior to publication</b> .
Section 4.	Intellectual Proper	rty Patents & Copyri	ghts	
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work?	☐ Yes 🗸 No

Tsunezuka 2



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Sortion 6
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Tsunezuka has nothing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Tsunezuka 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Seki 1



Section 1.	Identifying Inform	ation			
1. Given Name (Fi Nobuhiko	irst Name)	2. Surname (La Seki	st Name)	3. Date 06-January-2	020
4. Are you the cor	responding author?	Yes   ✓	No Correspor Toshiyuk	nding Author's Name ki Kozuki	
treatment of eld	ticenter, randomized pl	atients with prev		izumab or pemetrexed plus bo vanced non-squamous non-sm	
Section 2.	The Work Under Co	onsideration (	for Publication		
any aspect of the s statistical analysis, Are there any rel If yes, please fill o	stitution <b>at any time</b> receisubmitted work (including etc.)? levant conflicts of intereout the appropriate info	ive payment or se but not limited to est? Yes ormation below.	rvices from a third party o grants, data monitorin No  If you have more tha	r (government, commercial, privang board, study design, manuscrip n one entity press the "ADD" b	ot preparation,
Name of Institut	be removed by pressing		onal Non-Financial	Other? Comments	
Chugai Pharma				Honoraria	
-illy Japan				Honoraria	
Sanofi Aventis				Honoraria	
Cartina					
Section 3.	Relevant financial	activities outs	ide the submitted	l work.	
of compensation clicking the "Add Are there any rel	n) with entities as descrid +" box. You should replevant conflicts of intere	ibed in the instruport relationshiplest?  Yes	uctions. Use one line for the state were <b>present</b> on the line for the	nave financial relationships (reg for each entity; add as many lin during the 36 months prior t	nes as you need by
it yes, piease fill (	out the appropriate info	ormation below.			
Name of Entity		Grant? Pers	onal Non-Financial Support?	Other? Comments	
Astra7eneca			7 -	Honoraria	

Seki 2



Name of Entity	Grant?	-	Non-Financial	Other?	Comments
Boehringer Ingelheim		Fees •	Support?		Honoraria, Research funding
Taiho Pharmaceutical		✓			Honoraria
Daiichi Sankyo		<b>✓</b>			Honoraria
Ono Pharmaceutical		<u> </u>			Honoraria
Bristol-Myers Squibb		<b>✓</b>			Honoraria
MSD Oncology		<b>✓</b>			Honoraria
Nihon Medi-Physics		<b>✓</b>			Research funding
Do you have any patents, whether planned, pending or issued, broadly relevant to the work?					
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.					
Section 6. Disclosure Stateme	nt				
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.					
Dr. Seki reports personal fees from Chugai Pharma, personal fees from Lilly Japan, personal fees from Sanofi Aventis, during the conduct of the study; personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Taiho Pharmaceutical, personal fees from Daiichi Sankyo, personal fees from Ono Pharmaceutical, personal fees from Bristol-Myers Squibb, personal fees from MSD Oncology, personal fees from Nihon Medi-Physics, outside the submitted					

Seki 3

work;.



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Seki 4



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Harada 1



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Toshiyuki	2. Surname (Last Name) Harada	3. Date 06-January-2020
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Toshiyuki Kozuki
•	atients with previously un	plus bevacizumab or pemetrexed plus bevacizumab for treated advanced non-squamous non-small-cell lung
Section 2. The Work Under Co	onsideration for Public	cation
	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descr	ibed in the instructions. Us port relationships that wer est?	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication.
Name of Entity	Grant? Personal Noi	n-Financial Other? Comments
Boehringer Ingelheim		→ Honoraria
Hisamitsu Pharmaceutical Co.,Inc		<b>✓</b> Honoraria
GlaxoSmithKline K.K.		<b>✓</b> Honoraria
Section 4. Intellectual Proper	rty Patents & Copyrig	ghts
Do you have any patents, whether plan	,	

Harada 2



c .: =	
Section 5.	Relationships not covered above
	ationships or activities that readers could perceive to have influenced, or that give the appearance of cing, what you wrote in the submitted work?
Yes, the follow	ing relationships/conditions/circumstances are present (explain below):
✓ No other relation	onships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements Ials may ask authors to disclose further information about reported relationships.
Section 6.	
Section 6.	Disclosure Statement
Based on the abov below.	e disclosures, this form will automatically generate a disclosure statement, which will appear in the box
-	s other from Boehringer Ingelheim, other from Hisamitsu Pharmaceutical Co.,Inc, other from K.K., outside the submitted work; .

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Harada 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Inform	ation		
1. Given Name (First Name) Nobukazu	2. Surname (Last Name) Fujimoto		3. Date 06-January-2020
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Autho Toshiyuki Kozuki	or's Name
5. Manuscript Title Open-label, multicenter, randomized ph treatment of elderly (aged ≥75 years) pa 6. Manuscript Identifying Number (if you kn	atients with previously un		
Section 2. The Work Under Co	onsideration for Publi	cation	
Did you or your institution <b>at any time</b> recei any aspect of the submitted work (including statistical analysis, etc.)?			
Are there any relevant conflicts of intere	est? ✓ Yes No		
If yes, please fill out the appropriate info	ormation below. If you hav	ve more than one enti	ty press the "ADD" button to add a row.
Excess rows can be removed by pressing	g the "X" button.		
Name of Institution/Company	Grant	n-Financial other?	Comments
Chugai Pharmaceutical Co			
Section 3			
Section 3. Relevant financial	activities outside the	submitted work.	
Place a check in the appropriate boxes i of compensation) with entities as descriclicking the "Add +" box. You should rep	activities outside the son the table to indicate whe bed in the instructions. U	ether you have financ se one line for each er	ntity; add as many lines as you need by
Place a check in the appropriate boxes i of compensation) with entities as descriclicking the "Add +" box. You should repart there any relevant conflicts of interests."	n the table to indicate who bed in the instructions. Uport relationships that we est?	ether you have financ se one line for each er	ntity; add as many lines as you need by
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep	n the table to indicate who bed in the instructions. Uport relationships that we est?	ether you have financ se one line for each er	ntity; add as many lines as you need by
Place a check in the appropriate boxes i of compensation) with entities as descriclicking the "Add +" box. You should repart there any relevant conflicts of interests."	n the table to indicate who bed in the instructions. Uport relationships that we est?   Yes No ormation below.	ether you have financese one line for each er	ntity; add as many lines as you need by
Place a check in the appropriate boxes i of compensation) with entities as descriclicking the "Add +" box. You should repart there any relevant conflicts of interests."	n the table to indicate who bed in the instructions. Uport relationships that we est?  Yes Noormation below.	ether you have finance one line for each erre present during the one-financial	ntity; add as many lines as you need by
Place a check in the appropriate boxes i of compensation) with entities as descriclicking the "Add +" box. You should repart there any relevant conflicts of interest lf yes, please fill out the appropriate info	n the table to indicate who bed in the instructions. Uport relationships that we est?  Yes No primation below.  Grant? Personal Fees?	ether you have financese one line for each er	ntity; add as many lines as you need by a 36 months prior to publication.
Place a check in the appropriate boxes i of compensation) with entities as descriclicking the "Add +" box. You should repart there any relevant conflicts of interesting the please fill out the appropriate info	n the table to indicate who bed in the instructions. Uport relationships that we est?  Yes Noormation below.	ether you have finance one line for each erre present during the one-financial	atity; add as many lines as you need by a 36 months prior to publication.  Comments



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Boehlinger Ingerheim		<b>✓</b>			Consultancy	
Hisamitsu Pharmaceutical		<b>✓</b>			Honoraria	
Section 4. Intellectual Bronout						
Intellectual Propert	y Pate	ents & Co <sub>l</sub>	pyrights			
Do you have any patents, whether plann	ed, pend	ing or issue	ed, broadly releva	nt to the	work? Yes 🗸 No	
Section 5. Relationships not c	overed	above				
Are there other relationships or activities potentially influencing, what you wrote in Yes, the following relationships/conditions/cir  ✓ No other relationships/conditions/cir  At the time of manuscript acceptance, joe On occasion, journals may ask authors to	n the sub litions/cir cumstan urnals wi	cumstance ces that pro	rk? es are present (expessent a potential of ers to confirm and	olain belo conflict o	w): f interest sary, update their disclosure staten	nents.
Section 6. Disclosure Stateme	nt					
Based on the above disclosures, this form below.	n will auto	omatically (	generate a disclos	sure state	ment, which will appear in the box	
Dr. Fujimoto reports personal fees from ( Kyorin, personal fees from Ono, personal personal fees from Hisamitsu Pharmaceu	l fees froi	m Brystol-N	Neyers Squib, pers			



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation		
Given Name (First Name)     Akihiro	2. Surname (Last Name) Bessho		3. Date 06-January-2020
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Autho Toshiyuki Kozuki	or's Name
5. Manuscript Title Open-label, multicenter, randomized ph treatment of elderly (aged ≥75 years) pa 6. Manuscript Identifying Number (if you kno	itients with previously un		
Section 2. The Work Under Co	onsideration for Public	cation	
Did you or your institution <b>at any time</b> receivany aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intere	but not limited to grants, da		
If yes, please fill out the appropriate info Excess rows can be removed by pressing	rmation below. If you hav	ve more than one ent	ity press the "ADD" button to add a row.
Name of Institution/Company	Grant•	n-Financial upport?	Comments
Chugai Pharmaceutical			Honoraria
Eli Lilly			Honoraria
Section 3. Relevant financial a	activities outside the s	submitted work.	
Place a check in the appropriate boxes ir of compensation) with entities as described clicking the "Add +" box. You should rep	bed in the instructions. Us	se one line for each e	ntity; add as many lines as you need by
Are there any relevant conflicts of intere			
If yes, please fill out the appropriate info	rmation below.		
Name of Entity	Grant	n-Financial upport?	Comments
AstraZeneca			Honoraria, Research funding
Ono Pharmaceutical			Honoraria, Research funding



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
Bristol-Myers Squibb		<b>✓</b>			Honoraria		
Pfizer		<b>✓</b>			Honoraria, Research funding		
Boehringer Ingelheim		$\checkmark$			Honoraria		
Novartis		<b>✓</b>			Honoraria		
AbbVie		<b>✓</b>			Research funding		
Chugai Pharmaceutical		<b>✓</b>			Honoraria		
Daiichi Sankyo		<b>✓</b>			Honoraria		
Section 4. Intellectual Propert	y Pate	ents & Cop	pyrights				
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volumes No							
Section 5. Relationships not c	overed	above					
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?							
Yes, the following relationships/conditions/circumstances are present (explain below):							
✓ No other relationships/conditions/circumstances that present a potential conflict of interest							
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							
Section 6. Disclosure Stateme	nt						
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.							
Dr. Bessho reports personal fees from Chugai Pharmaceutical, personal fees from Eli Lilly, during the conduct of the study; personal fees from AstraZeneca, personal fees from Ono Pharmaceutical, personal fees from Bristol-Myers Squibb, personal fees from Pfizer, personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from AbbVie, personal fees from Chugai Pharmaceutical, personal fees from Daiichi Sankyo, outside the submitted work;							



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Takamura 1



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Kei	2. Surname (Last Name) Takamura	3. Date 06-January-2020
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Toshiyuki Kozuki
·	atients with previously unt	plus bevacizumab or pemetrexed plus bevacizumab for reated advanced non-squamous non-small-cell lung
Section 2. The Work Under Co	onsideration for Public	ation
	but not limited to grants, dat	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	ubmitted work.
of compensation) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e <b>present during the 36 months prior to publication</b> .
Section 4. Intellectual Proper	rty Patents & Copyrig	hts
Do you have any patents, whether plan	ned, pending or issued, bro	oadly relevant to the work? ☐ Yes ✓ No

Takamura 2



Section 5.	
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	ationships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements Irnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Takamura ha	ns nothing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Takamura 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Takahashi 1



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Kazuhisa	2. Surname (Last Name) Takahashi	3. Date 06-January-2020
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Toshiyuki Kozuki
•	atients with previously unt	plus bevacizumab or pemetrexed plus bevacizumab for created advanced non-squamous non-small-cell lung
Section 2. The Work Under Co	onsideration for Public	ation
		a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of intere	est? Yes No	
Section 3. Polyvant financial		where it is a discount.
Kelevant linancial	activities outside the s	
of compensation) with entities as descri clicking the "Add +" box. You should rep	bed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e present during the 36 months prior to publication.
Are there any relevant conflicts of intered If yes, please fill out the appropriate info		
Name of Entity	Grant? Personal Nor	Other? Comments
Chugai-pharm	<b>/</b>	
Eli Lilly		
Section 4. Intellectual Proper	ty Patents & Copyrig	ıhts
Do you have any patents, whether plant		

Takahashi 2



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Takahashi reports grants from Chugai-pharm, grants from Eli Lilly, outside the submitted work; .

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Takahashi 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Satouchi 1



Section 1. Identifying Inforn	nation							
Given Name (First Name)     Miyako	2. Surname (Last Name) Satouchi	3. Date 06-January-2020						
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Aut						
<ul> <li>5. Manuscript Title</li> <li>Open-label, multicenter, randomized p</li> <li>treatment of elderly (aged ≥75 years) p</li> <li>6. Manuscript Identifying Number (if you keep)</li> </ul>	atients with previously ur	-	•					
Section 2. The Work Under C	onsideration for Publi	cation						
Did you or your institution <b>at any time</b> receany aspect of the submitted work (including statistical analysis, etc.)?			ment, commercial, private foundation, etc.) for study design, manuscript preparation,					
Are there any relevant conflicts of inter-	est? ✓ Yes No							
	-	ve more than one e	ntity press the "ADD" button to add a row.					
Excess rows can be removed by pressing								
Name of Institution/Company	Grant	n-Financial Support?	? Comments					
Chugai Pharmaceutical	<b>✓</b>		Research Expenses, Lecture Fees					
Eli Lilly Japan	<b>✓</b>		Research Expenses, Lecture Fees					
Section 3. Relevant financial	activities outside the	submitted work.						
	ibed in the instructions. U	se one line for each	ncial relationships (regardless of amount entity; add as many lines as you need by the 36 months prior to publication.					
•	Are there any relevant conflicts of interest?  Ves  No							
If yes, please fill out the appropriate inf	ormation below.							
Name of Entity	Grant	n-Financial Other	? Comments					
Taiho Pharmaceutical			Lecture Fees					
Pfizer Japan	✓		Research Expenses, Lecture Fees					

Satouchi 2



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
AstraZeneca	<b>✓</b>	<b>✓</b>			Research Expenses, Lecture Fees		
Boehringer Ingelheim	<b>✓</b>	<b>✓</b>			Research Expenses, Lecture Fees		
ristol-Myers Squibb Research Expenses,Lecture Fees							
Ono Pharmaceutical	<b>✓</b>	<b>✓</b>			Research Expenses, Lecture Fees		
Novartis Pharmaceutical	<b>✓</b>	<b>✓</b>			Research Expenses, Lecture Fees		
MSD	<b>✓</b>	<b>✓</b>			Research Expenses, Lecture Fees		
gnyta	<b>✓</b>				Research Expenses		
Abbvie	<b>✓</b>				Research Expenses		
PS international	<b>✓</b>				Research Expenses		
akeda	<b>✓</b>				Research Expenses		
Section 4. Intellectual Property Patents & Copyrights  Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No  Section 5. Relationships not covered above							
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  Yes, the following relationships/conditions/circumstances are present (explain below):							
✓ No other relationships/conditions/c							
At the time of manuscript acceptance is	ournals wi	ll ask autho	ors to confirm and	d, if neces	sary, update their disclosure statemer		

Satouchi 3

On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

**Disclosure Statement** 

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Satouchi reports grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Eli Lilly Japan, during the conduct of the study; personal fees from Taiho Pharmaceutical, grants and personal fees from Pfizer Japan, grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Novartis Pharmaceutical, grants and personal fees from MSD, grants from Ignyta, grants from Abbvie, grants from EPS international, grants from takeda, outside the submitted work;

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Satouchi 4



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation		
Given Name (First Name)  Terufumi	2. Surname (Last Name) Kato	1	3. Date 09-May-2020
4. Are you the corresponding author?	Yes ✓ No	Corresponding Autho Toshiyuki Kozuki	or's Name
5. Manuscript Title Open-label, multicenter, randomized ph treatment of elderly (aged ≥75 years) pa 6. Manuscript Identifying Number (if you kn TLCR-19-734	atients with previously (		
Section 2. The Work Under Co	onsideration for Pub	lication	
Did you or your institution <b>at any time</b> recei any aspect of the submitted work (including statistical analysis, etc.)?			
Are there any relevant conflicts of intere	est? ✓ Yes No	1	
If yes, please fill out the appropriate info		ave more than one enti	ty press the "ADD" button to add a row.
Excess rows can be removed by pressing	g the "X" button.		
Name of Institution/Company	Grant? Personal N	Support? Other?	Comments
Chugai	<b>✓</b>		
Section 3. Polovant financial	activities outside the	e submitted work	
nelevalit lilialitial	activities outside the	e submitted work.	
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep	bed in the instructions.	Use one line for each er	ntity; add as many lines as you need by
Are there any relevant conflicts of interes	est? 🗸 Yes 🗌 No	•	
If yes, please fill out the appropriate info	ormation below.		
Name of Entity	Giant	Ion-Financial Other?	Comments
Abbvie	Fees?	Support?	
Astellas			
AstraZeneca	✓ ✓		



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Boehringer-Ingelheim		<b>✓</b>			
Bristol-Myers Squibb	<b>✓</b>	<b>✓</b>			
Chugai	<b>✓</b>	$\checkmark$			
Eli Lilly	<b>√</b>	$\checkmark$			
Kyorin	<b>√</b>				
Kyowa Kirin	<b>√</b>	<b>✓</b>			
Merck Biopharma	<b>√</b>	<b>✓</b>			
MSD	<b>√</b>	<b>✓</b>			
Nitto Denko		<b>✓</b>			
Novartis	✓	<b>✓</b>			
Ono	<b>√</b>	<b>✓</b>			
Pfizer	<b>✓</b>	<b>✓</b>			
Regeneron	<b>✓</b>				
Sumitomo Dainippon		<b>✓</b>			
Taiho	<b>√</b>	<b>✓</b>			
Takeda		<b>✓</b>			
F. Hoffmann-La Roche		<b>✓</b>			

Section 4.	Intellectual Property Patents & Copyrights	
Do you have any	patents, whether planned, pending or issued, broadly relevant to the work?	<b>✓</b> No

Section 5.	Relationships not covered above							
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?							
Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest								
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.							
Section 6.	Disclosure Statement							

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Kato reports grants and personal fees from Chugai, during the conduct of the study; grants and personal fees from Abbvie, grants from Astellas, grants and personal fees from AstraZeneca, personal fees from Boehringer-Ingelheim, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Chugai, grants and personal fees from Eli Lilly, grants from Kyorin, grants and personal fees from Kyowa Kirin, grants and personal fees from Merck Biopharma, grants and personal fees from MSD, personal fees from Nitto Denko, grants and personal fees from Novartis, grants and personal fees from Ono, grants and personal fees from Pfizer, grants from Regeneron, personal fees from Sumitomo Dainippon, grants and personal fees from Taiho, personal fees from Takeda, personal fees from F. Hoffmann-La Roche, outside the submitted work;

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

upplied by the entity, travel paid by the entity, writing assistance,
dministrative support, etc.



Section 1. Identifying Inform	nation								
1. Given Name (First Name) Takehito	2. Surname (Last Name) Shukuya		3. Date 06-January-2020						
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's N Toshiyuki Kozuki	lame						
5. Manuscript Title Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small-cell lung 6. Manuscript Identifying Number (if you know it)									
Section 2. The Work Under Co	onsideration for Public	ration							
Did you or your institution <b>at any time</b> received any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interes	but not limited to grants, da	. , ,	•						
Section 3. Relevant financial	activities outside the s	submitted work.							
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intere If yes, please fill out the appropriate info	ibed in the instructions. Use port relationships that werest?   Yes No Primation below.	se one line for each entity re present during the 36	; add as many lines as you	need by					
Name of Entity	Grant? Personal Nor	n-Financial other? Co	omments						
MSD	<b>✓</b>								
Boehringer Ingelheim	<b>✓</b>								
Nichi-Iko Pharmaceutical Co.									
Astrazeneca									
Chugai Pharma	<b>□</b> ✓								
Daiichi Sankyo									
Ono Pharmaceutical									
Bristol-Myers Squibb									



Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other?	Comments	
Eli Lilly and Company					
Novartis					
Taiho Pharma					
Section 4. Intellectual Propert	y Patents & Co	pyrights			
Do you have any patents, whether plann	ed, pending or issu	ed, broadly releva	ant to the v	work? Yes No	
Section 5. Relationships not c	overed above				
Are there other relationships or activities potentially influencing, what you wrote i		•	influenced	l, or that give the appearance of	
Yes, the following relationships/cond	litions/circumstanc	es are present (ex	plain belo	w):	
No other relationships/conditions/cir					
At the time of manuscript acceptance, jo On occasion, journals may ask authors to				• •	ments.
Section 6. Disclosure Stateme	nt				
Based on the above disclosures, this form below.		generate a disclo	sure state	ment, which will appear in the bo	x
Dr. Shukuya reports grants and personal from Nichi-Iko Pharmaceutical Co., perso Daiichi Sankyo, personal fees from Ono I and Company, personal fees from Novar	onal fees from Astra Pharmaceutical, pe	zeneca, personal : rsonal fees from B	fees from ristol-Mye	Chugai Pharma, personal fees fror rs Squibb, personal fees from Eli L	m



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Yamashita 1



Section 1. Ident	ifying Information							
1. Given Name (First Name Natsumi	2. Surnan Yamashi	ne (Last Name) ta	3. Date 06-January-2020					
4. Are you the correspondi	ing author? Yes	✓ No	Corresponding Author's Name Toshiyuki Kozuki					
-	ed ≥75 years) patients witl		lus bevacizumab or pemetrexed plus bevacizumab fo eated advanced non-squamous non-small-cell lung	or				
Section 2. The W	/ork Under Considerat	ion for Publica	ition					
any aspect of the submitted statistical analysis, etc.)?	Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No							
Section 3. Relev	ant financial activities	outside the su	bmitted work.					
of compensation) with e	ntities as described in the You should report relatio	instructions. Use	her you have financial relationships (regardless of am one line for each entity; add as many lines as you nee present during the 36 months prior to publication	ed by				
Section 4. Intelle	ectual Property Pate	nts & Copyrigl	nts					
Do you have any patents	s, whether planned, pendi	ng or issued, bro	adly relevant to the work? Yes Vo					

Yamashita 2



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Yamashita has nothing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Yamashita 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your



	Section 1. Identifying Informa	ntion							
	1. Given Name (First Name) Hiroaki		me (Last Namo	e)		3. Date 07-January-2020			
	4. Are you the corresponding author?	Yes	<b>✓</b> No	Correspon Toshiyuki	or's Name				
5. Manuscript Title Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small-cell lung 6. Manuscript Identifying Number (if you know it)									
	Section 2. The Work Under Co	nsidera	tion for Pu	blication					
	Did you or your institution <b>at any time</b> received any aspect of the submitted work (including lestatistical analysis, etc.)?  Are there any relevant conflicts of interest	out not lin		s, data monitoring	_	•	etc.) for		
	Section 3. Relevant financial a	ctivities	s outside th	ne submitted	work.				
	Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should report there any relevant conflicts of interest lf yes, please fill out the appropriate information.	ed in the ort relation of the orthogonal ort	e instructions onships that Yes \(\bigcup\) N	s. Use one line fo were <b>present</b> d	or each e	ntity; add as many lines as you ne	ed by		
	Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
A	MED	<b>✓</b>							
T	akeda				<b>✓</b>	Research fund			
V	ISD				<b>✓</b>	Research fund			
0	no				<b>✓</b>	Research fund			
A	strazeneca				<b>✓</b>	Research fund			
V	1erck				✓	Research fund			
C	hugai				<b>✓</b>	Research fund			
T	aiho				<b>✓</b>	Research fund			



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments				
Bristol				<b>✓</b>	Research fund				
Eli Lilly				<b>✓</b>	Research fund				
Daiich Sankyo				<b>✓</b>	Research fund				
Section 4.	Dot								
Do you have any patents, whether plann	*			nt to the	work? Yes 🗸 No				
Section 5. Relationships not c	overed	above							
Are there other relationships or activities potentially influencing, what you wrote i				nfluence	d, or that give the appearance of				
Yes, the following relationships/cond	litions/cir	cumstance	s are present (exp	olain belo	w):				
✓ No other relationships/conditions/cir	cumstan	ces that pre	esent a potential o	conflict o	finterest				
At the time of manuscript acceptance, jo On occasion, journals may ask authors to					•	nts.			
Section 6. Disclosure Stateme									
Disclosure Stateme	nt								
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.									
Dr. Okamoto reports grants from AMED, from Merck, other from Chugai, other from the submitted work; .						ſ			



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Shinkai 1



Section 1.	Identifying Inform	nation		
1. Given Name (First Name) Tetsu		2. Surname (Last Name) Shinkai	3. Date 06-January-2020	
4. Are you the corresponding author?		☐ Yes ✓ No	Corresponding Author's Name Toshiyuki Kozuki	
5. Manuscript Title Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small-cell lung 6. Manuscript Identifying Number (if you know it)				
Section 2.	The Work Under Co	onsideration for Public	ation	
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No				
Section 3.	Relevant financial	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo				
Section 4.	Intellectual Proper	rty Patents & Copyrig	hts	
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo				

Shinkai 2



Section 5.			
Section 5.	Relationships not covered above		
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?			
Yes, the following relationships/conditions/circumstances are present (explain below):			
✓ No other relationships/conditions/circumstances that present a potential conflict of interest			
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.			
Section 6.	Disclosure Statement		
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.			
Dr. Shinkai has no	thing to disclose.		

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Shinkai 3